Exclusive Product License AgreementExclusive Product License Agreement • March 15th, 2024 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive Product License Agreement (this “Agreement”) is made and entered into as of this 23rd day of March, 2021 (the “Effective Date”) by and between Vaccinex, Inc., having offices at 1895 Mt. Hope Avenue, Rochester NY 14620 USA (“Vaccinex”), and Surface Oncology, Inc. having offices at 50 Hampshire St, 8th Floor, Cambridge, MA 02139 (“Surface”). Vaccinex and Surface are sometimes referred to herein each individually as a “Party” and collectively as the “Parties.”
Exhibit 10.3 WADE COOK FINANCIAL CORPORATION EXCLUSIVE PRODUCT LICENSE AGREEMENT This Exclusive Product License Agreement (the "Agreement") is made as of this 30th day of June, 1998 (the "Effective Date"), by and between Wade Cook Financial...Exclusive Product License Agreement • November 16th, 1998 • Wade Cook Financial Corp • Services-educational services
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...Exclusive Product License Agreement • August 5th, 2021 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
